Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $805,919.40 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,999 shares of the business’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $80.60, for a total transaction of $805,919.40. Following the sale, the senior vice president directly owned 14,219 shares in the company, valued at $1,146,051.40. This trade represents a 41.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, September 21st, Arjun Agarwal sold 533 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.75, for a total value of $51,034.75.
• On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The stock was sold at an average price of $95.71, for a total value of $53,597.60.
• On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $92.23, for a total value of $872,403.57.
• On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $106.66, for a total value of $1,066,600.00.

Oruka Therapeutics Stock Down 3.7%

Shares of ORKA opened at $73.87 on Friday. The stock has a 50-day moving average of $92.99 and a two-hundred day moving average of $80.08. Oruka Therapeutics, Inc. has a one year low of $25.11 and a one year high of $115.51.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities analysts expect that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ORKA. Mizuho set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, September 3rd. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. UBS Group raised their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a research note on Wednesday, October 7th. Finally, Guggenheim restated a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $128.91.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Oruka Therapeutics in the second quarter worth about $474,916,000. Jupiter Topco LLC acquired a new stake in Oruka Therapeutics during the second quarter worth about $130,968,000. Bank of America Corp DE acquired a new stake in Oruka Therapeutics during the second quarter worth about $33,578,000. Braidwell LP purchased a new position in Oruka Therapeutics during the second quarter valued at approximately $26,473,000. Finally, Atika Capital Management LLC purchased a new position in Oruka Therapeutics during the first quarter valued at approximately $11,277,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.